It’s important to be a proactive PNH patient. You’ll want to know how to how to find a doctor and manage your treatment.

PNH is a rare, chronic, and life-threatening blood disease in which uncontrolled complement activation leads to the destruction of red blood cells through intravascular hemolysis and ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Novartis Pharma AG. Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal ...

Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal nocturnal haemoglobinuria (PNH). These findings ...

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy ...

The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and haemolysis control in people with paroxysmal nocturnal hemoglobinuria (PNH) 1COMMODORE 3 is the ...

The global market size for PNH is reported at $3.8 billion dollars in 2023 and projected at over $11.7 billion dollars in 2034. Currently, ...

The dominance of the C5 inhibitors Ultomiris and Soliris in PNH was one of the reasons AstraZeneca’s $39 billion acquisition of the rare-disease-focused Alexion looked like such a good move in 2020.

(RTTNews) - Swiss drug maker Novartis AG (NVS) announced Thursday that Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve ...